Hey readers! Here's something you don't hear every day: a diabetes therapy grown, in part, from a herd of genetically engineered cattle in South Dakota is now recruiting patients across four continents. That's the SAB-142 story, and it's the headliner this week. Let's dig in.
🧬 SAB-142: a stage 3 T1D trial that's actively recruiting
S.D.-born biotech advances potential Type 1 diabetes therapy through global trial reports that SAB Biotherapeutics is enrolling patients age 12 and older in SAFEGUARD, a global pivotal registrational trial of SAB-142 for stage 3 Type 1 diabetes. – SiouxFalls.Business
The scope matters here. Enrollment is happening across more than 60 clinical sites in Australia, New Zealand, Europe, and the U.S., with a global goal of 159 participants. SAB expects to complete enrollment by the end of 2026 and anticipates top-line data in the second half of 2027. If you or a family member is newly diagnosed and within the trial window, this is a real, in-progress opportunity worth raising with your care team.
So what is SAB-142? It's described as a fully human anti-thymocyte immunoglobulin (hATG), designed to modify the disease rather than simply manage its symptoms. The idea is to preserve insulin-producing beta cells and slow progression, so people can better hold onto their own insulin regulation. Patients still take insulin during this phase; the goal is to keep the immune system from finishing the job it started.
"It's been a long road but to be in this kind of a registrational trial for a potentially what we would call a disease-modifying drug is significant," Sullivan said. "This isn't used to treat the disease. It's a treatment to modify the disease, to halt it from advancing at whatever stage."
A note on the evidence so far, because it's important to be honest about where things stand. SAB previously ran a Phase 1 trial, and added data reported C-peptide preservation and improved glycemic control in all four Type 1 participants who received SAB-142. That's encouraging, but the company is refreshingly candid about the limits of such a small group:
"The data is reported, but it's not statistical because of the low number of patients," he said. "It literally is just encouragement that we have the potential for efficacy."
That's exactly why the larger SAFEGUARD trial exists. Small signals need bigger, controlled studies to become something you can act on.
📋 The business and supply picture behind the trial
Two Q2 2026 updates fill in the operational side, and they're reassuring for anyone worried about whether a small biotech can actually see a program like this through.
SAB BIO's Type 1 Diabetes Trial Has More Than 60 Sites Recruiting confirms more than 60 sites are activated and recruiting across the U.S., Australia, New Zealand, the U.K., and the EU, with enrollment on track to complete in Q4 2026 and topline data expected in the second half of 2027. – StockTitan
"The second quarter was marked by strong execution as we advanced SAB-142 across key clinical and operational milestones. Enrollment in our registrational SAFEGUARD study remains on track for completion in Q4 this year, with more than 60 sites actively recruiting."
The same update flags an interesting supply move: SAB began constructing a second farm facility in South Dakota to expand its Tc-Bovine platform capacity and build in redundancy. If that sounds unusual, it is. SAB-142 is produced through genetically engineered cattle, so a backup herd is essentially a backup manufacturing line, reducing the risk that a single-site problem derails supply down the road.
SAB BIO Reports Q2 2026 Financial Results adds the numbers behind the runway: cash, cash equivalents, and investment securities of $208.0 million as of June 30, 2026, providing operational runway through 2028. – GlobeNewswire
That release also details PRISE-hATG, a companion Phase 3, randomized, double-blind, placebo-controlled study of 108 participants, backed by a Breakthrough T1D grant. It targets stage 3 patients who are 100 days to two years from diagnosis, with beta-cell preservation over 12 months as a primary objective. Together, SAFEGUARD and PRISE-hATG give SAB-142 two shots at building the evidence base for a stage 3 disease-modifying label.
🕰️ The bigger theme: catching T1D earlier
SAB-142 is part of a wider shift toward intervening before beta cells are fully lost. Several stories this week orbit the same idea.
From Germany, the Federal Joint Committee's teplizumab assessment offers a look at how these early-stage therapies get judged once trials end. – AbangeLabs Editorial
On 6 August 2026, G-BA found an indication of a non-quantifiable added benefit for teplizumab (Teizeild) in stage 2 T1D versus watchful waiting, when the goal is delaying progression to stage 3. The decision leaned on the TN-10 trial (76 participants), which recorded a statistically significant delay to clinical disease of roughly two years.
G-BA recorded a statistically significant delay in progression to clinical type 1 diabetes, with median manifestation delayed by about two years, but kept the benefit non-quantifiable because of limits in population transferability, dosing differences from the authorised product, sparse data, and safety trade-offs.
Why it matters for the SAB-142 crowd: reviewers are increasingly evaluating early therapies on time-to-progression endpoints, but they still demand a clear line from trial data to real patient benefit. SAFEGUARD's larger enrollment is well-timed for exactly that kind of scrutiny.
Another angle comes from prevention research. Can BMI Normalization Reduce Progression to Type 1 Diabetes? covers new work from the TrialNet Pathway to Prevention Study. – Medscape
Among 833 autoantibody-positive participants who started with overweight or obesity, 26.8% reached a normal BMI over a median 4.1-year follow-up, and those whose BMI normalized had a 48% lower adjusted risk of progressing to stage 3 (HR 0.652; P = .022). The association was strongest in participants under 18 and did not hold in adults.
"At this point, we have to be very cautious because this is an observational study, not a clinical trial. The only way we can prove causality is a prospective study where we try an intervention and see what happens," she noted.
A useful reminder that association is not causation, but a promising lead for a future intervention trial in children.
🔬 Also on the research bench
A few more developments worth a quick look:
vTv Therapeutics' Q2 update says its Phase 3 CATT1 trial of cadisegliatin, an oral adjunctive therapy for T1D aimed at the hypoglycemia burden, should complete enrollment in Q3 2026, with a Phase 2a "Hybrid CATT1" closed-loop trial planned before year end. – MarketScreener
Rice University researchers report an IL-10-producing hydrogel capsule that shielded implanted insulin cells and kept blood sugar controlled in diabetic mice for more than 100 days, nearly five times longer than unprotected cells, with encouraging nonhuman primate results. Still preclinical, but a smart approach to protecting islet transplants without systemic immunosuppression. – Scientific Frontline
Creative Medical Technology Holdings received a USPTO Notice of Allowance for an exosome-based immunotherapy patent tied to its MyeloCelz platform; the program remains investigational with no new clinical data. – GlobeNewswire
Rajasthan expanded Mission Madhuhari, adding AI-powered retinopathy screening and digital patient tracking; since launching in November 2024, it had registered more than 1,700 patients with free insulin and supplies by December 2025. – Convergence Now
The common thread across all of it: the field is pushing to preserve beta cells and catch T1D earlier, from immunoglobulins and oral adjuncts to cell shields and public-health screening. SAB-142's SAFEGUARD trial is one of the more advanced tests of that thesis, and with enrollment wrapping this year, 2027 data is worth watching for.
Take care of yourselves, and if the trial window fits your situation, it's a conversation worth having with your clinician.